Disease · MONDO_0005211

ovarian serous adenocarcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ovarian serous adenocarcinoma. Diseases, record MONDO_0005211. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005211

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ovarian serous adenocarcinoma; Open Targets
Open Targets ID: MONDO_0005211; Open Targets
Other names: ovarian serous carcinoma, ovary serous adenocarcinoma, serous adenocarcinoma of ovary, serous adenocarcinoma of the ovary, serous carcinoma of ovary, serous carcinoma of the ovary; Open Targets
Disease Ontology: DOID:0050933; Disease Ontology
Disease Ontology: DOID:5744; Disease Ontology
NCI Thesaurus: C7550; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 10 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AURANOFIN	CHEMBL1366	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
AVUTOMETINIB	CHEMBL3264002	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DEFACTINIB	CHEMBL3137331	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OLAPARIB	CHEMBL521686	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PAMIPARIB	CHEMBL4112930	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SIROLIMUS	CHEMBL413	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TISLELIZUMAB	CHEMBL4297840	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets26

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PARP1	PARP 1, 2 and 3	2	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/142	Drugs and targets
PARP2	PARP 1, 2 and 3	2	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor	Phase 2	https://conductscience.org/library/genes/10038	Drugs and targets
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
CYP19A1	Aromatase	1	Cytochrome P450 19A1 inhibitor	Phase 2	https://conductscience.org/library/genes/1588	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
MAP2K1	Dual specificity mitogen-activated protein kinase kinase 1	1	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5604	Drugs and targets
MAP2K2	Dual specificity mitogen-activated protein kinase kinase 2	1	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor	Phase 2	https://conductscience.org/library/genes/5605	Drugs and targets
PARP3	PARP 1, 2 and 3	1	PARP 1, 2 and 3 inhibitor	Phase 2	https://conductscience.org/library/genes/10039	Drugs and targets
PTK2	Focal adhesion kinase 1	1	Focal adhesion kinase 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5747	Drugs and targets
PTK2B	Protein-tyrosine kinase 2-beta	1	Protein tyrosine kinase 2 beta inhibitor	Phase 2	https://conductscience.org/library/genes/2185	Drugs and targets

1 to 10 of 26

See all 26 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00753545	Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer	Phase 2	265	2013-03-11	Ovarian Cancer	OLAPARIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03456700	Auranofin and Sirolimus in Treating Participants With Ovarian Cancer	Phase 2	22	2020-07-02	Ovarian Serous Tumor, Recurrent Ovarian Carcinoma	AURANOFIN, SIROLIMUS	Open Targets' reading of its record	ClinicalTrials.gov
NCT05044871	Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer	Phase 2	108		Ovarian Cancer	BEVACIZUMAB, PACLITAXEL, PAMIPARIB, TISLELIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03126812	Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer	Phase 1/2	33		Ovarian Cancer Stage IV, Peritoneal Cancer, Fallopian Tube Cancer	CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT06394804	A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer	Phase 2	20		Low-Grade Serous Ovarian Cancer	AVUTOMETINIB, DEFACTINIB, LETROZOLE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Olaparib 400 mg bd vs Placebo: serious adverse events	31 of 136	11 of 128	264	NCT00753545

Source Trial comparisons

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41114938	DERIVED	1	PubMed
39695768	DERIVED	1	PubMed
38658024	DERIVED	1	PubMed
35254001	DERIVED	1	PubMed
35170751	DERIVED	1	PubMed
27824811	DERIVED	1	PubMed
27617661	DERIVED	1	PubMed
27062051	DERIVED	1	PubMed
24882434	DERIVED	1	PubMed
22452356	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005211

GET https://conductscience.org/api/diseases/v1/MONDO_0005211/targets?page=2

API reference For AI assistants